Basic Information
| LncRNA/CircRNA Name | MIRAT |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | MEK inhibitor (GSK1120212), BRAF inhibitor PLX-4720 | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | melanoma |
| ICD-0-3 | NA |
| Methods | RNA-seq, Microarray, RIP |
| Sample | melanoma tissues, cell lines (DO4, MM415) |
| Expression Pattern | up-regulated |
| Function Description | we identify a novel cytoplasmic intergenic lincRNA (MIRAT), which is upregulated following prolonged MAPK inhibition in NRAS mutant melanoma. our results present MIRAT's direct modulatory efect on the MAPK pathway and highlight the relevance of cytoplasmic lncRNAs as potential targets in drug resistant cancer. |
| Pubmed ID | 30026510 |
| Year | 2018 |
| Title | The lincRNA MIRAT Binds to IQGAP1 and Modulates the MAPK Pathway in NRAS Mutant Melanoma. |
External Links
| Links for MIRAT | GenBank HGNC NONCODE |
| Links for melanoma | OMIM COSMIC |